• Kenneth Hachikian has been elected chairman of the board of Cambridge Heart (Tewksbury, Massachusetts), replacing Robert Khederian, who resigned the position but will continue to serve as a director. The board also elected Jeffrey Wiggins as a new director. Wiggins is a former principal of Dresdner RCM Capital Management. In addition, Louis Blumberg has resigned from the board. Hachikian has served on the company's board since July 2004 and is a member of its audit committee and chairman of the nominating and compensation committees. Cambridge Heart makes products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest.
  • OxyBand Technologies (San Francisco) has named Olivier Postel, PhD, to lead the company's biomedical technology development and expand its intellectual property portfolio. Prior to joining OxyBand, Postel was director of process engineering and integration at dpiX. OxyBand makes therapeutic gas technology for health, cosmetic and consumer care.
  • Christopher Cabell, MD, has been named chief medical and scientific officer for Quintiles Transnational (Research Triangle Park, North Carolina), succeeding Oren Cohen, MD, recently named senior VP, clinical research strategies. Most recently, Cabell was global cardiovascular/endocrine therapeutic group leader within the medical and scientific services group and provided cardiology expertise for Quintiles Electrocardiogram Services. Quintiles Transnational provides a broad range of professional services in drug development, commercialization and strategic partnering for the pharmaceutical, biotechnology and medical device industries.
  • Steven Harris has been appointed to the Public Company Accounting Oversight Board (PCAOB) of the Securities and Exchange Commission. Harris, a former long-time Senate Banking Committee official who played a key role in the legislation that created the PCAOB, was unanimously selected by the Commission to fill a recent vacancy on the Board. The PCAOB, established by the Sarbanes-Oxley Act of 2002, oversees the audits of the financial statements of public companies.